Listed

Regeneron Pharmaceuticals, Inc.

REGNNasdaqCIK 872589HealthcareFiscal year ends Dec 31

Reports and events: 327 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Regeneron Pharmaceuticals, Inc., Reports and events
FiledFormWhat it isAccession number
2023-06-1416:07 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-23-071187
2023-05-0407:14 ET10-QQuarterly reportPeriod 2023-03-310001804220-23-000016
2023-05-0407:11 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-23-000015
2023-04-2116:01 ETDEF 14AProxy statement0001308179-23-000728
2023-04-1707:37 ET8-K5.02 Departure or appointment of officers or directors0001104659-23-045897
2023-04-1007:01 ET8-K2.02 Results of operations0001104659-23-043287
2023-03-2916:01 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001104659-23-038299
2023-02-0609:23 ET10-KAnnual reportPeriod 2022-12-310001804220-23-000008
2023-02-0307:06 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-23-000005
2023-01-0908:49 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-23-002091
2022-12-2016:01 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001104659-22-128613
2022-11-0307:25 ET10-QQuarterly reportPeriod 2022-09-300001804220-22-000031
2022-11-0307:19 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-22-000029
2022-10-0307:17 ET8-K5.02 Departure or appointment of officers or directors0001104659-22-104901
2022-08-0307:21 ET10-QQuarterly reportPeriod 2022-06-300001804220-22-000023
2022-08-0307:08 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-22-000020
2022-06-1516:11 ET8-K5.07 Shareholder vote results0001104659-22-071446
2022-06-0207:36 ET8-K1.01 Entry into a material agreement0001104659-22-067375
2022-05-0407:17 ET10-QQuarterly reportPeriod 2022-03-310001804220-22-000015
2022-05-0407:08 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-22-000013
2022-04-2116:09 ETDEF 14AProxy statementPeriod 2022-06-100000930413-22-000787
2022-03-0806:15 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001104659-22-031232
2022-02-0709:25 ET10-KAnnual reportPeriod 2021-12-310001804220-22-000007
2022-02-0407:29 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-22-000004
2022-01-1006:02 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-22-002403
2021-11-0407:19 ET10-QQuarterly reportPeriod 2021-09-300001804220-21-000033
2021-11-0407:12 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-21-000031
2021-09-1616:01 ET8-K1.01 Entry into a material agreement0001104659-21-116352
2021-08-0507:11 ET10-QQuarterly reportPeriod 2021-06-300001804220-21-000025
2021-08-0506:59 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-21-000023
2021-06-1616:36 ET8-K5.07 Shareholder vote results0001104659-21-082035
2021-05-0607:21 ET10-QQuarterly reportPeriod 2021-03-310001804220-21-000017
2021-05-0607:12 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-21-000015
2021-04-2316:11 ETDEF 14AProxy statementPeriod 2021-06-110000930413-21-000869
2021-02-0809:13 ET10-KAnnual reportPeriod 2020-12-310001804220-21-000008
2021-02-0507:34 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-21-000006
2021-01-1516:01 ET8-K1.01 Entry into a material agreement0001104659-21-004699
2021-01-1106:03 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-21-002614
2021-01-0506:03 ET8-K5.02 Departure or appointment of officers or directors0001104659-21-000538
2020-11-0507:48 ET10-QQuarterly reportPeriod 2020-09-300001804220-20-000030
2020-11-0507:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-20-000028
2020-08-1906:00 ET8-K1.01 Entry into a material agreement0001104659-20-096661
2020-08-1216:32 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits0001104659-20-093924
2020-08-0507:36 ET10-QQuarterly reportPeriod 2020-06-300001804220-20-000022
2020-08-0507:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001804220-20-000020
2020-07-0707:28 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure0001104659-20-081559
2020-06-1717:10 ETSC 13D/AOwnership report, active investor, amended0001140361-20-014084
2020-06-1616:33 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-20-073794
2020-05-2916:15 ETSC 13D/AOwnership report, active investor, amended0001140361-20-012717
2020-05-2916:07 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-20-067752

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.